Synthesis, biological evaluation and 3D-QSAR studies of imidazolidine-2,4-dione derivatives as novel protein tyrosine phosphatase 1B inhibitors

• Published in: European journal of medicinal chemistry 2015-10, Vol.103, p.91-104
• Main Authors: Wang, Mei-Yan, Jin, Yuan-Yuan, Wei, Hui-Yu, Zhang, Li-Song, Sun, Su-Xia, Chen, Xiu-Bo, Dong, Wei-Li, Xu, Wei-Ren, Cheng, Xian-Chao, Wang, Run-Ling
• Format: Article
• Language: English
• Subjects: CoMFA/CoMSIA; Docking; Dose-Response Relationship, Drug; Enzyme Inhibitors - chemical synthesis; Enzyme Inhibitors - chemistry; Enzyme Inhibitors - pharmacology; Humans; Imidazolidine-2,4-dione; Imidazolidines - chemical synthesis; Imidazolidines - chemistry; Imidazolidines - pharmacology; Models, Molecular; Molecular Structure; Protein Tyrosine Phosphatase, Non-Receptor Type 1 - antagonists & inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 1 - metabolism; PTP1B; Quantitative Structure-Activity Relationship; Structure-Activity Relationship; Synthesis
• ISSN: 0223-5234; 1768-3254
• DOI: 10.1016/j.ejmech.2015.08.037

Protein tyrosine phosphatase 1B (PTP1B) plays a vital role in the regulation of insulin sensitivity and dephosphorylation of the insulin receptor, so PTP1B inhibitors may be potential agents to treat type 2 diabetes. In this work, a series of novel imidazolidine-2,4-dione derivatives were designed, synthesized and assayed for their PTP1B inhibitory activities. These compounds exhibited potent activities with IC50 values at 0.57–172 μM. A 3D-QSAR study using CoMFA and CoMSIA techniques was carried out to explore structure activity relationship of these molecules. The CoMSIA model was more predictive with q2 = 0.777, r2 = 0.999, SEE = 0.013 and r2pred = 0.836, while the CoMFA model gave q2 = 0.543, r2 = 0.998, SEE = 0.029 and r2pred = 0.754. The contour maps derived from the best CoMFA and CoMSIA models combined with docking analysis provided good insights into the structural features relevant to the bioactivity, and could be used in the molecular design of novel imidazolidine-2,4-dione derivatives. This paper reports the synthesis, PTP1B inhibitory activities and CoMFA/CoMSIA studies of a series of novel imidazolidine-2,4-dione derivatives. [Display omitted] •A series of novel imidazolidine-2,4-dione derivatives were synthesized.•Compounds exhibited potent PTP1B inhibitory activities at 0.57–172 μM.•Highly predictive 3D-QSAR models were developed using CoMFA/CoMSIA techniques.•The key structural features for activity were explored using 3D contour maps.•A docking analysis was performed to study the receptor–ligand interactions.